Introduction
For the full potential of cancer gene therapy to be realized, it is necessary that improved means be developed by which the expression and/or functional activity of potentially useful genes can be efficiently targeted to tumor cells in vivo. [1] [2] [3] In principle, such targeting will help ensure maximal therapeutic benefit while reducing the likelihood that normal tissues will suffer damage. Among the various strategies that have been explored in this regard, those involving transcriptional regulation have proven especially useful [4] [5] [6] [7] and a number of innovative techniques have been developed that permit the rapid isolation of promoter/enhancer elements with the required specificity. 8 Encouraging results have also been obtained by altering the natural tropism of viral vectors through genetic or other means so as to permit selective transduction of particular cell types. 9 Finally, although less well developed, we and others have had some success exploiting alternative splicing and other post-transcriptional processes for targeting purposes. [10] [11] [12] Although such approaches are clearly promising, it remains the case that no single targeting strategy is likely to possess sufficient specificity to ensure that gene expression is restricted entirely to the cell type of interest. However, if several independent approaches are used in combination, it may be possible to dramatically reduce non-targeted effects. Further benefit may be gained by the inclusion of additional layers of control. Our interest in this regard has focused on the development of strategies that link a particular therapeutic response (for example, cell death, immune stimulation and so on) to the differential expression within the tumor microenvironment of certain activating signals (for example, cytokines, adhesion proteins and so on). 12 The example described in this study was designed to exploit the production within a tumor site of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF).
Currently, there is much interest in the important role played by angiogenesis in tumor development and pathogenesis. 13, 14 As oxygen is consumed as it diffuses through metabolically active tissues, tumors that are unable to induce the formation of new blood vessels will remain small and localized. Continued tumor growth is thus critically dependent upon the ability to trigger an angiogenic response. Studies carried out in recent years have helped elucidate the molecular and cellular events that regulate this process. 13, 14 It is now evident that various genetic changes, including the expression of certain tumor suppressor genes and/or oncogenes, or the exposure of tumor cells to various microenvironmental stimuli such as hypoxia, induce the secretion of one or more soluble mediators (angiogenic factors) 15 that act on endothelial cells lining established blood vessels in adjacent tissues to trigger and coordinate the complex series of molecular and cellular events that give rise ultimately to new vessels. 15 In some circumstances, circulating endothelial cell precursor cells may also be recruited into sites of active angiogenesis. 16 Importantly, the abnormal and dysregulated nature of angiogenesis in tumor tissues results in a structurally abnormal vasculature that may be functionally compromised producing areas within tumors that are poorly perfused. 17 The hypoxic and/or other conditions that result may act to stimulate further angiogenesis supporting continued tumor growth and ultimately, local tissue invasion and metastasis. 17 Although numerous soluble mediators possess angiogenic activity, the cytokine VEGF has been shown to play a key role in tumor development. 18, 19 VEGF expression is dramatically upregulated in the majority of the tumors, particularly in regions of hypoxia. 15, 20 Circulating levels of VEGF are also elevated in some cancer patients. 21 Importantly, recent evidence suggests that in addition to producing VEGF, certain tumor cell types may coexpress the corresponding VEGF receptors VEGFR1/Flt-1 and/ or VEGFR2/Flk-1. In some cases, the coreceptors neuropilin-1 and -2, which play an important role in regulating the response to VEGF in some cell types, may also be present. 22 These findings raise the possibility that in addition to stimulating angiogenesis, VEGF may act in an autocrine and/or paracrine fashion to stimulate tumor cell proliferation. 23, 24 Given the diverse functions attributed to the molecule, it comes as little surprise that correlations have been noted between the expression of VEGF and various disease parameters including local invasion, metastatic propensity and poor prognosis. 21, [25] [26] [27] Further emphasizing the important role played by VEGF in tumorigenesis, compounds that neutralize VEGF or block either the interaction of VEGF with its receptors or the transduction of signals upon ligand binding exhibit potent antitumor activity. [28] [29] [30] [31] Taken together, the differential expression and diverse activities attributed to VEGF within the tumor microenvironment raise the possibility that this molecule could perhaps be exploited in the development of targeted cancer gene therapy. The approach we have taken in this regard is to generate a cDNA encoding a chimeric cellsurface protein in which the extracellular ligand-binding domain of human VEGFR2 (Flk-1) is fused in frame to the membrane-spanning and cytoplasmic death domains of the pro-apoptotic protein Fas. It was hypothesized that rather than transducing the growth-promoting and proangiogenic signals normally triggered by Flk-1 upon ligand binding, this chimeric protein would instead induce apoptotic death (Figure 1) . In this report, we show that 
Materials and methods

Cell lines
The VEGF-deficient cell line WT8, generated by stable transfection of parental 786-O renal carcinoma cells with a wild-type von-Hippel-Lindau tumor suppressor gene cDNA, was a generous gift from Dr Michael Ohh, University of Toronto, Canada. von-Hippel-Lindau functions as a key component of a multisubunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor-1a for proteasomal degradation in the presence of oxygen. 32 As such, it acts as a negative regulator of various hypoxia-inducible transcription factor-1a-regulated hypoxia-inducible mRNAs including VEGF and other pro-angiogenic cytokines (for example, transforming growth factor-a), which are reduced to near undetectable levels when WT8 cells are grown under normoxic conditions. 33, 34 In support of this conclusion, enzyme-linked immunosorbent assay studies carried out as described below have demonstrated that media conditioned by WT8 cells contain barely detectable levels of VEGF (that is, o50 pg ml À1 ) (data not shown). The tumor cell lines DU145 (prostatic carcinoma), T24 (transitional bladder carcinoma) and MCF7 (mammary adenocarcinoma) were obtained from the American Type Culture Collection (Manassas, VA). 293 cells (adenovirus (Ad) type 5-transformed human embryonic kidney cells) were obtained from Q-BIOgene (Carlsbad, CA). All cell lines were maintained at 37 1C in an atmosphere containing 5% CO 2 in Dulbecco's minimal essential medium supplemented with 5-10% fetal bovine serum, 2 mM L-glutamine, 50 U ml À1 penicillin and 50 mg ml À1 streptomycin sulfate (Dulbecco's minimal essential medium þ 10% fetal bovine serum). The full-length Fas cDNA (B1.5 kb) was also generated by PCR. In this instance, Jurkat cDNA was used as a template together with the following primer pair:
Antibodies and cytokines
. The reaction conditions were identical to those described above. A product of appropriate size was isolated following gel electrophoresis and sequenced. It was found to be identical to the previously published Fas sequence with the exception of an A to G substitution at position 1117 that results in a single amino-acid change of Glu to Gly at position 297 located within the cytoplasmic domain of the mature protein.
Digestion of the full-length Fas cDNA with BamHI generated a B0.5 kb fragment encoding the membranespanning and cytoplasmic death domains of the molecule. This was fused in frame to the cDNA encoding the extracellular ligand-binding domain of Flk-1, which had also been digested with BamH1. For expression studies, both the full-length Fas cDNA and the resultant chimeric Flk-1/Fas cDNA were cloned into the Epstein-Barr virusbased episomal expression vector pCEP4 (BD Biosciences).
Construction and purification of an adenoviral vector encoding Flk-1/Fas
An Ad encoding the Flk-1/Fas chimeric protein (Ad. Flk-1/Fas) was generated using the AdEasy vector system (Q-BIOgene). Briefly, an expression cassette containing pCMV, Flk-1/Fas and a polyA signal was released from the episomal expression vector pCEP4 by Sal1 digestion. The fragment obtained was then blunted using T4 DNA polymerase (Life Technologies, Gaithersburg, MD) and cloned into the EcoRV site of the transfer vector pShuttle (Q-BIOgene). The PmeI-linearized vector was then cotransformed with the supercoiled adenoviral backbone vector pAdEasy-1 into the recombination-competent Escherichia coli strain BJ5183. The linearized shuttle vector was inserted into the adenoviral genome by homologous recombination, and recombinant adenoviral plasmids were screened by restriction enzyme analysis. The recombinant adenoviral construct was then digested with PacI and transfected into 293 cells. The transfected cells were reseeded 24 h later and overlaid with Dulbecco's minimal essential medium þ 7.5% fetal calf serum (FCS) containing 1.25% Seaplaque agarose. After 10-14 days, the untransfected 293 cells became confluent, and the transfected 293 cells became rounded and detached, producing Ad that subsequently infected nearby cells, forming a plaque. Adenoviral clones from each plaque were expanded and assayed for expression of the Flk-1/ Fas protein. One clone was chosen and expanded by sequential infection of 293 cells followed by purification over cesium chloride step gradients. Viral supernatants were dialyzed at 4 1C against multiple changes of 10 mM Tris pH 8.0, 1 mM MgCl 2 , 3% sucrose and stored at À80 1C. Viral titer was determined by testing the ability of serial dilutions to lyse 293 cells. A previously generated Ad encoding murine IL-3 was used as a control. . Following extensive washing in Hank's balanced salt solution containing 2% FCS, the cells were incubated for a further 30 min on ice with fluorescein isothiocyanate-conjugated rabbit anti-goat secondary antibody (2 mg ml À1 ). After additional washing, the cells were resuspended in Hank's balanced salt solution þ 2% FCS containing 1 mg ml À1 propidium iodide to facilitate the identification and exclusion of dead cells and analyzed on a FACSCalibur (Becton-Dickinson Immunocytometry Systems, Mountain View, CA).
Western blot analysis 293 cells were electroporated with pCEP4, pCEP4.Fas or pCEP4.Flk-1/Fas plasmid DNA, harvested 2 days later using PBS containing 3 mM EDTA, and the expression of both the Flk-1/Fas transgene and endogenous Fas determined by western blot analysis. Briefly, the cells were washed in PBS and their membranes solubilized by incubating the pellets for 15 min on ice in 10 mM Tris (pH 7.5), 150 mM NaCl, 2 mM EDTA and 1% NP-40 at B2 Â 10 7 cells per ml lysis buffer. Nuclei and detergentinsoluble material were removed by centrifugation and the lysates stored at À80 1C until required. Thawed samples were added to an equal volume of non-reducing sample buffer (125 mM Tris, 20% (v v À1 ) glycerol, 4.6% (w v
À1
) SDS (pH 6.8)) and incubated at 100 1C for 5 min. Total cellular proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The filters were incubated overnight at 4 1C in PBS containing 5% (w v À1 ) milk protein then probed with either the Fas death domain-specific mAb 3D5 (2 mg ml À1 in Hank's balanced salt solution þ 2% FCS) or a polyclonal anti-Flk-1 Ab (2 mg ml À1 in Hank's balanced salt solution þ 2% FCS). The CD44 mAb 4A4 was used as a control to ensure equal protein loading and transfer. After extensive washing, filters were incubated with a 1:100 dilution of the appropriate horseradish peroxidase-conjugated secondary antibody. After additional washing, the filters were developed in enhanced chemiluminescence (ECL) solution (Amersham Pharmacia Biotech, Uppsala, Sweden) and protein products imaged on a photographic film (Amersham Life Sciences, Buckinghamshire, UK).
Apoptotic response of VEGF-deficient WT8 cells WT8 cells seeded in six-well tissue culture plates (Nunc, Fisher Scientific, Pittsburgh, PA) were incubated with Ad.Flk-1/Fas or control Ad.IL-3 at a multiplicity of infection of B10. Forty-eight hours later, rhVEGF 165 was added at a final concentration of 200 ng ml
, and after a further 24 h of culture, the percentage of apoptotic cells was determined by FACS analysis after staining with fluorescein isothiocyanate-labeled Annexin V and propidium iodide.
Quantitation of VEGF expression
A semi-quantitative reverse transcription PCR approach was used to determine the expression of VEGF mRNA in various tumor cell lines. Single-strand cDNA was prepared from oligo-dT-primed mRNA (5 mg) isolated from 293, T24, PC3 and DU145. The resultant cDNAs were used as PCR templates. The primers used correspond to sequences in the VEGF exons 3 (5 0 -GAGA CCCTGGTGGACATCTTCCAGGAGTACCC-3 0 ) and 8 (5 0 -GGCTCCTTCCTCCTGCCCGGCTCA CCGCC TCG-3 0 ), permitting the amplification of each of the three major alternatively spliced VEGF isoforms. Products were separated by electrophoresis on a 1% agarose gel and photographed after staining with ethidium bromide. Primers corresponding to the actin sequence (5 0 -GCTGTGCTATCCCTGTACGCCTCTGGC-3 0 and 5 0 -GATGGAGTTGAAGGTAGTTTCG TG-3 0 ) were used as a control. After 25 cycles (94 1C
The level of VEGF protein present in tissue culture supernatants conditioned by various tumor cell lines was determined using a commercial enzyme-linked immunosorbent assay kit (R&D Systems).
Induction of DU145 apoptosis DU145 cells growing in a six-well tissue culture plate (Nunc) were infected with Ad.Flk-1/Fas or a control adenoviral vector encoding murine IL-3 (Ad.IL-3) at a multiplicity of infection of 10. Photographs were taken 48 h later using a Zeiss IM-35 inverted microscope.
Clonogenic survival assay
The effect of Flk-1/Fas expression on the long-term survival and proliferation of tumor cell lines was determined using a standard clonogenic assay. Plasmids rather than adenoviral vectors were used for these studies, as it is necessary that all potential clonogens express the transgene. Although adenoviral transduction is very efficient, the vector described above does not include a means of selecting transduced cells. Although the expression of the transgene can be virtually assured if sufficient virus is used, high multiplicity of infection may be toxic. In contrast, the pCEP4-based episomal vector includes a selectable marker (hygromycin resistance) that can be used to ensure that all cells that could potentially give rise to a colony have taken up the Flk-1/Fas construct. Briefly, pCEP4, pCEP4.Fas or pCEP4.Flk-1/Fas plasmid DNA, purified using the QIAfilter Plasmid Midi Kit (QIAGEN, Valencia, CA), was introduced into 293, PC3 and T24 cells by electroporation as described below. Tumor cells were harvested by trypsinization and resuspended in PBS at 1-2 Â 10 7 cells per ml. Twenty micrograms of plasmid DNA were added to 4 Â 10 6 cells and transferred to a 2-mm gap cuvette and electroporated using the BTX ECM 600 Electroporator System (BTX, San Diego, CA). The settings for 293 cells were 270 V, capacitance 400 mF and resistance setting of 72 O producing time constants ranging from 3.0 to 3.5 ms. The settings for T24 were 280 V, capacitance setting 500 mF and resistance setting of 48 O producing time constants ranging from 3.3 to 3.9 ms. The settings for PC3 were 280 V, capacitance setting 300 mF and resistance setting of 48 O producing time constants ranging from 2.2 to 2.5 ms. Immediately after the electroporation, the cells were transferred into 35 ml Dulbecco's minimal essential medium þ 10% fetal bovine serum and plated in BD Falcon 150 mm Integrid tissue culture dishes (BD Biosciences, San Jose, CA). Hygromycin B (Sigma) was added 24 h later to a final concentration of either 200 mg ml À1 (293 and PC3) or 250 mg ml À1 (T24) to select cells that have taken up and expressed plasmid DNA. Around 14 days later, plates were fixed and stained with methylene blue and the number of hygromycin-resistant colonies determined.
Results
For Flk-1/Fas to be effective in a cancer gene therapy setting, it is necessary that the chimeric protein is stably expressed at a reasonable level on the surface of transduced cells. To confirm that this is indeed the case, an adenoviral vector encoding Flk-1/Fas (Ad.Flk-1/Fas) was constructed and used to introduce and express the corresponding cDNA in a panel of histologically distinct tumor cell types. Cells were harvested 2 days after infection and surface expression of Flk-1/Fas determined by FACS analysis using an antibody directed against the extracellular domain of Flk-1. As shown in Figure 2 , high level expression of the transgene was evident on the surface of all lines tested including the bladder cell line T24, the prostate tumor cell line DU145, the breast carcinoma MCF7 and the Ad type 5-transformed human embryonic kidney cell line 293. To ensure that the chimeric Flk-1/Fas protein is processed in an appropriate manner, western blot analysis was carried out. In this case, the full-length Flk-1/Fas cDNA was cloned into the Epstein-Barr virus-based episomal expression vector pCEP4 and plasmid DNA introduced into 293 cells by electroporation. Transfected cells were harvested 2 days later, membrane lysates prepared and western blots probed with a polyclonal antibody directed against the extracellular domain of Flk-1 or an mAb directed against the death domain of Fas (mAb 3D5). A control mAb directed against CD44 was used to confirm equal loading. As shown in Figure 3 , the results obtained confirm the presence within transfected cells of a protein with an apparent molecular weight of around 130 kDa that reacts with both the anti-Flk-1 and anti-Fas death domain antibodies. Monomeric Fas itself has a molecular weight of between 37 and 50 kDa depending on the nature and extent of post-translational modification. Although a diffuse species of this size is present in cells transfected with pCEP4.FAS, little if any expression is evident in control 293 cells or in 293 cells transfected with pCEP.Flk-1/Fas (Figure 3) .
For the Flk-1/Fas chimera to be useful in the context of cancer gene therapy, it is essential that it kills target cells only in the presence of the corresponding ligand (for example, VEGF). To ensure that this is indeed the case, Flk-1/Fas was introduced and expressed in WT8, a VEGF-deficient cell line generated by stable transfection of 786-0 renal carcinoma cells with a wild-type vonHippel-Lindau cDNA. Although not completely negative for VEGF, enzyme-linked immunosorbent assay studies demonstrated that WT8 cells secrete barely detectable levels of the cytokine (data not shown). As shown in Figure 4 , FACS analysis confirmed efficient gene transfer and transient high-level expression of the Flk-1/Fas protein on the surface of WT8 cells 24 h after infection with an adenoviral vector encoding the chimeric molecule (Ad.Flk-1/Fas). As expected, given the low levels of VEGF produced by the transduced cells, little spontaneous apoptotic death occurred following infection with Ad.Flk-1/Fas as determined by Annexin V staining ( Figure 5) . A significant apoptotic response could, however, be induced upon the addition of exogenous recombinant VEGF ( Figure 5) .
In contrast to WT8, most established tumor cell lines constitutively produce VEGF. Among the lines examined in initial studies, the prostate line DU145 was shown, using a semi-quantitative reverse transcription PCR approach, to express the highest level of VEGF mRNA ( Figure 6 ). Intermediate levels of VEGF mRNA were detected within 293 and PC3 cells whereas, under the particular culture conditions employed, the T24 bladder cell line expressed only low levels of VEGF mRNA 
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( Figure 6 ). Examination of conditioned supernatants using a commercial enzyme-linked immunosorbent assay kit (R&D Systems) confirmed that the variation in VEGF mRNA production observed between the different tumor cell lines was reflected at the protein level ( Figure 6 ). As expected, given their high constitutive production of VEGF, DU145 cells rapidly exhibited a series of morphological changes characteristic of apoptosis upon infection with Ad.Flk-1/Fas including rounding up, detachment and membrane blebbing ( Figure 7 ). Finally, a standard clonogenic survival assay was utilized to determine the impact of Flk-1/Fas expression on tumor cell survival and/or proliferation. Briefly, 293, PC3 and T24 cells were electroporated with a control pCEP4 plasmid or pCEP4-based plasmids encoding either Flk-1/Fas or the full-length Fas cDNA. Transfectants Figure 8 ). It is important to emphasize, however, that T24 cells are not intrinsically defective in Fas-mediated apoptosis and can be readily killed if transfected with other Fas chimeras that recognize more highly expressed ligands including, for example, PDGFreca/Fas (manuscript in preparation).
Discussion
The success of cancer gene therapy is critically dependent upon the development of safe, efficient and practical means that permit the selective targeting of tumor tissue in vivo. Linking the induction of a therapeutic effect such as cytotoxicity or immune stimulation to the presence of signals that occur differentially within the tumor microenvironment is an attractive approach, as even if the gene in question is inappropriately expressed in non-targeted tissues, a response will not occur unless the required triggering signal is also present. In such circumstances, some 'leakiness' in the transcriptional and/or posttranscriptional targeting of tumor cells can be tolerated.
Although defects in apoptosis often arise in the course of malignant progression, these are normally relative rather than absolute. Thus, although certain of the cell lines used in this study, including the bladder line T24, are resistant to conventional Fas agonists, such as the antiFas mAb C-11, apoptotic death could be induced upon infection with an adenoviral vector encoding FasL. 35 Clearly, the magnitude of the stimulus is a key component, and resistance can be overcome if the trigger used is sufficiently active or present at a high-enough level.
The ability of VEGF to trigger an apoptotic response upon binding to the chimeric Flk-1/Fas receptor described in this study came as a surprise as induction of apoptosis through Fas or other members of the tumor necrosis factor receptor family is generally thought to be dependent on ligand-mediated trimerization. 36 In agreement with this conclusion, the natural ligands that bind these various receptors, including FasL, are all homotrimers. VEGF, in contrast, is a homodimer, and triggering of downstream signal transduction events upon binding to VEGFR1/Flt-1 or VEGFR2/Flk-1 requires only that the receptors are dimerized. [37] [38] [39] There is, however, some evidence that dimerization of the Fas death domain may be sufficient to transmit an apoptotic signal, at least in some circumstances. Thus, FK1012, a membrane-permeable intracellularly active chemical in- ducer of Fas dimerization can induce thymocytes that express a conditional Fas receptor to undergo apoptosis in vivo. 40 Similarly, AP20187-mediated dimerization of an intracellular fusion protein consisting of the FK506-binding protein joined to Daxx induced an apoptotic response in the murine pro-B cell line, BAF3. 41 In physiological circumstances, dimeric Fas has been observed on human umbilical vein endothelial cells undergoing Fas-mediated anoikis. 42 An alternative possibility, supported by some recent evidence, is that Fas and other members of the tumor necrosis factor receptor family may form pre-assembled oligomers on the cell surface in the absence of the ligand. 43 In agreement with this finding, Fanzo et al. 44 have shown that Fas tends to cluster in distinct sphingolipid-rich membrane domains in response to stimuli that activate ligand-binding function. In such circumstances, the induction of apoptotic or other responses may not be as dependent upon the multimeric nature of the corresponding ligand. Irrespective of the mechanism involved, it seems likely that the oligomerization of Flk-1/Fas required for the induction of an apoptotic response upon ligand binding will be facilitated if the chimeric protein is highly expressed on the surface of transduced cells. Indeed, studies with other similar receptor chimeras suggest that ligand binding and the subsequent induction of apoptosis only occurs when the transgene in question is expressed above a certain critical threshold level. Although such studies emphasize the need for efficient gene expression, they also suggest that the inadvertent low-level expression that may occur in nontargeted tissues as a result of the 'leakiness' of a tissuespecific promoter may not produce cell death even in the presence of the corresponding ligand.
Whether the approach described in this manuscript is broadly applicable to other combinations of receptors and cytokines remains to be determined. Flt-1/Fas chimeras are active and can induce apoptosis in the presence of VEGF (data not shown). Similarly, we have found that a PDGFrecA/Fas chimera can induce the death of cells that express high levels of PDGFa (manuscript in preparation). Others have shown, however, that a chimera between the receptor for granulocyte colony-stimulating factor and Fas, similar in design to those described in this study, did not trigger an apoptotic response upon addition of granulocyte colony-stimulating factor although death could be induced if the chimeric receptor was cross-linked by antibody. 45 Presumably, success will be dictated by the characteristics of the receptor and cytokine combination used and in particular whether the degree of oligomerization induced upon ligand binding is adequate to trigger the necessary downstream signaling events.
Tumors that produce high levels of VEGF are obvious candidates for this form of targeted gene therapy. Among the more common malignancies, bladder cancer is particularly attractive in this regard as many of the delivery-, safety-and efficiency-related issues that have prevented clinical application of other promising gene therapy approaches do not apply, or are less significant, in the context of this malignancy. Large volumes of viral supernatants and other agents can be repeatedly introduced into the bladder and drained through a transurethral catheter. 46 Importantly, the basal lamina constitutes a very effective barrier to the systemic spread of intravesicularly administered agents and even when present at very high titers, little if any virus appears to escape from the bladder and infect other organs, greatly easing safety concerns. 47, 48 Moreover, the bladder can be readily accessed by cystoscopy permitting the biopsy of normal and tumor tissue allowing the efficacy of treatment to be repeatedly monitored in a minimally invasive manner.
The production of VEGF by bladder tumors was first described in 1993 49 and has been confirmed in numerous subsequent studies. 50 RNase protection analysis of tissue obtained by transurethral resection indicated that the levels of VEGF present within bladder tumors were at least 10 times higher than are seen in the surrounding normal urothelium, with the 121 amino-acid isoform tending to predominate, accounting for as much as 75% of the total. Upregulation of VEGF appears to be an early event in the evolution of bladder cancer and is a predictor of relapse and progression even in non-invasive superficial disease. [51] [52] [53] Interestingly, in one study, correlations were observed between tumor grade and the ratio of the various VEGF isoforms, with the levels of VEGF 121 in XpT2 tumors tending to be higher than in ppT1 tumors, whereas the opposite appeared to be the case for VEGF 206 and VEGF 189 . 54 In contrast, studies examining the relationship between overall VEGF expression and tumor progression and long-term patient survival have yielded conflicting results. 55 It has been postulated that differences in the results obtained by different groups reflect, at least in part, the involvement of various post-transcriptional regulatory processes in the control of VEGF expression, resulting in poor agreement between studies in which RNA-and protein-based approaches were used to relate the production of VEGF to clinical outcome. 53, 55, 56 Although often thought of as endothelial cell-specific, the VEGFRs Flt-1 and Flk-1 are expressed and functional on a number of non-endothelial cell types including retinal pigment epithelial cells, 57 Schwann cells, 57 pancreatic ductal epithelial cells, 58, 59 renal mesangial cells 60, 61 and certain subsets of both primitive and more mature hematopoietic cell types. [62] [63] [64] Aberrant VEGFR expression has also been noted on a number of malignant cell types and is a common feature in melanoma, 65 mesothelioma, 66 leukemia, 67 breast cancer 68, 69 and pancreatic ductal adenocarcinoma. 70 Of particular relevance, a high proportion of bladder tumor cells also appear to express Flk-1 and/or Flt-1. 54, 71, 72 Thus bladder tumor cells not only produce VEGF but may also show enhanced proliferation and/or migration in response to the cytokine. For example, in one recent study, endogenous VEGF was shown to stimulate proliferation of the Flk-1-positive transitional bladder tumor cell line T24. 72 This mitogenic response involved VEGF-dependent activation of protein kinase C, sphingosine kinase, Ras and the mitogen-activated kinases extracellular signal-regulated kinase-1 and -2. Interestingly, VEGF-induced activation of Ras (H-Ras and N-Ras) occurred in a Ras-guanine nucleotide exchange factorindependent manner suggesting the involvement of a novel Ras activation pathway.
Perhaps the major factor limiting the application of tumor cell-directed cytotoxic gene therapy is the relatively poor efficiency of current in vivo gene transfer techniques. This may be a particular problem with the Fas-based approach described herein, as bystander killing is unlikely to be induced. It is for this reason that gene therapy approaches employing Fas chimeras may prove most effective when used in conjunction with other treatments. The combination with radiation is especially attractive. Responsiveness to ionizing radiation is critically dependent upon the presence of oxygen and it has long been appreciated that hypoxic cells are relatively resistant and contribute to regrowth following treatment. However, as hypoxia is a potent inducer of VEGF production, these same cells are likely to be those most sensitive to killing with Flk-1/Fas. There are other treatments that elevate the production of VEGF within the tumor microenvironment including photodynamic therapy, 73 and here too benefits may be gained by the addition of Flk-1/Fas gene therapy.
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